



Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature

Senem Alanyalı¹, Emre Karaman¹, Murat Köylü¹, Ümit Kahraman², Sanem Nalbantgil³

¹Department of Radiation Oncology, Ege University Hospital, İzmir, Türkiye

²Department of Cardiovascular Surgery, Ege University Hospital, İzmir, Türkiye

³Department of Cardiology, Ege University Hospital, İzmir, Türkiye

ABSTRACT

The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.

Keywords: Left ventricular assist device; breast cancer; radiotherapy; case report

Cite this article as: Alanyalı S, Karaman E, Köylü M, Kahraman Ü, Nalbantgil S. Safe delivery of radiotherapy for breast cancer patient with left ventricular assist device: case report and review of the literature. Eur J Breast Health. 2025; 21(4): 379-383

Key Points

- Increasing use of left ventricular assist devices (LVAD) raises the likelihood that these patients would develop cancer requiring radiotherapy.
- Safe irradiation dose limits are better studied for cardiac implantable electronic devices but data on LVAD are scarce.
- This case report involves a breast cancer patient, required LVAD placement during chemotherapy and later was indicated with radiotherapy.
- With maximum and mean doses to whole LVAD system being 767 cGy and 227 cGy, respectively, no LVAD malfunction occurred throughout the follow-up period.
- LVAD does not necessarily contraindicate radiotherapy; risks and consequences should be evaluated in a multidisciplinary context.

Introduction

Advances in cardiac device technologies have led to an increased use of cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD) (1). With longer life expectancy in this patient population, the likelihood of cancer diagnosis, and thus the need for radiotherapy, also increases. While safe irradiation limits are more thoroughly studied for CIEDs, data regarding the safe irradiation of LVADs are scarce. Limited *in vitro* and *in vivo* studies indicate that radiotherapy doses up to 70 Gy, at the upper end of the therapeutic spectrum, may be administered safely. Herein, we report a case of breast cancer with a long follow-up for a patient with an *in situ* LVAD who was safely irradiated.

Case Presentation

A 41-year-old premenopausal female with a history of non-Hodgkin lymphoma, treated 25 years ago with chemotherapy, the details of which were unavailable, and no history of radiotherapy and no known comorbidity, presented with a right axillary mass. With consideration of lymphoma relapse, the patient underwent excisional biopsy, which resulted in lymph node metastasis of "invasive ductal carcinoma of breast". Bilateral mammography and ultrasound revealed a right breast upper outer quadrant lesion with malignant features. Tru-cut biopsy from breast lesion was consistent with invasive ductal carcinoma of breast (estrogen receptor +++; progesterone receptor -, human epidermal growth factor receptor 2 +++). The patient was thus initially

Corresponding Author:
Senem Alanyalı MD; senem.alanyali@ege.edu.tr

Received: 19.03.2025
Accepted: 08.06.2025
Epub: 04.08.2025
Available Online Date: 25.09.2025

diagnosed as T1N1 (stage II) breast cancer, and the oncological team started treatment with neoadjuvant chemotherapy. The initial phase of neoadjuvant chemotherapy, including four cycles of doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²), was completed with no adverse effects. After the first cycle of trastuzumab (8 mg/kg) + pertuzumab (840 mg) + docetaxel (75 mg/m²), the patient developed chest pain, shortness of breath, abdominal and lower extremity swelling and was diagnosed with dilated cardiomyopathy with low left ventricular ejection fraction of only 25% due to cardiotoxic systemic therapy. With no clinical improvement with medical therapy, a HeartWare HVAD (HeartWare Inc., Miami Lakes, FL, USA) was implanted, stabilizing her hemodynamics. Subsequently, the patient underwent total mastectomy and axillary dissection, with pathology revealing complete response. After careful multidisciplinary evaluation of the cardiac and oncologic status of the patient, adjuvant radiotherapy was planned. Written informed consent was taken from the patient.

Radiotherapy Simulation and Treatment Course

External LVAD parts were carefully observed, and a 5 mm-thick lead shield box for the external system controller was produced. The patient was placed on a breast board with arms above the head (Figure 1). Radiotherapy was prescribed to the right chest wall and regional lymphatics (axillary levels 1–4) for 50 Gy in 25 fractions. Intracorporeal LVAD parts were delineated separately (Figure 2). An anterior supraclavicular field and opposed 6 MV photons to the right chest wall area (Figure 3) were used for treatment to minimize radiation exposure to LVAD subparts. Radiation doses received by separate parts of LVAD is shown in Table 1. A cardiology nurse and device specialist were available for each treatment and conducted daily pre- and post-treatment measurements of flow and power as a surrogate for LVAD performance, which showed no major measurable alterations. Treatment was completed without any device errors or malfunctions (Table 2). During cardiologic follow-up visits, no signs of LVAD malfunction were observed.

Oncological follow-up continued with no local or systemic breast cancer recurrence. Forty-nine months after breast cancer diagnosis and 41 months after LVAD placement, she had a non-traumatic intracranial hemorrhage and underwent decompression surgery, and unfortunately, died due to sepsis during post-op care.



Figure 1. Patient positioned on breast board and extracorporeal system control unit placed between the legs of the patient, covered with lead shield box

Discussion and Conclusion

Deciding whether to give radiotherapy for patients with LVAD may be challenging, considering the scarcity of high-quality data. Herein, we describe a breast cancer patient with LVAD who safely received adjuvant radiotherapy. Accumulated doses caused no disturbance to LVAD function during follow-up. To the best of our knowledge, this is the first patient who had a HeartWare LVAD and received adjuvant radiation therapy for primary breast cancer.

In terms of the safety of radiotherapy with LVADs, a review by Spano et al. (2), reported that LVAD performance was unaffected for doses of up to 70-75 Gy which are considered in therapeutic range for both photon and proton beams in several *in vitro* studies. However, Sindhu et al. (3) found, while the pump components were resilient to the 70 Gy of proton irradiation, the driveline part showed functional disturbance at 30 Gy of continuous proton irradiation, necessitating careful evaluation of various parts of the LVAD in dose-volume analysis.

To date, only twelve case reports, including eighteen cases, have been published (2, 5-13). These reports evaluated radiotherapy safety in various tumor sites and with different LVAD brands [HeartMate, Abbott, Chicago, IL, USA (HM II-III)]; HeartWare, HeartWare Inc., Miami Lakes, FL (HW); Thoratec, Thoratec, Pleasanton, CA; Novacor LVAD Atlas II VR SN, St. Jude Medical, Saint Paul, Minnesota, US. In most studies, patients were implanted with a HeartMate LVAD.




Figure 2. Delineation of heart (blue), aorta (pink), and LVAD parts [yellow: LVAD pump (D_{max}: 24 cGy, D_{mean}: 9 cGy); cyan: outflow graft (D_{max}: 767 cGy, D_{mean}: 227 cGy); orange: driveline (D_{max}: 199 cGy, D_{mean}: 52 cGy)]

LVAD: Left ventricular assist devices

Table 1. Radiation doses received by different parts of LVAD

	Maximum dose (cGy)	Mean dose (cGy)
LVAD pump	24	9
Outflow graft	767	227
Driveline	199	52
LVAD: Left ventricular assist devices		




Figure 3. Radiotherapy dose distribution in axial and coronal views and LVAD placement (light orange) adequate target coverage was achieved (PTV_Chestwall D95%: 95.2%, PTV_Supraclavicular: D95%: 99.5%). Heart D_{mean} : 86 cGy

LVAD: Left ventricular assist devices

Table 2. Measured device flow and power parameters during treatment

	Flow (L/min)	Power (watt)
1 st Fraction - beginning	3.3	3.2
6 th Fraction - week 2	3.9	3.4
11 th Fraction - week 3	3.7	3.4
16 th Fraction - week 4	3.9	3.4
21 st Fraction - week 5	4.2	3.6
25 th (Last) fraction	3.3	3.2

Eight studies evaluated nine patients treated with conventionally fractionated radiotherapy, while six studies evaluated nine patients treated with stereotactic body radiotherapy (SBRT) (2, 8, 9, 13, 15). One study reported a lung cancer patient treated with proton beams (11). Studies reporting cardiac ablative therapies with SBRT for arrhythmias were reviewed by Benali et al. (4), with no LVAD-related complications after SBRT and are not included in this review. In fifteen cases, radiotherapy fields involved the thoracic region, in two cases, encompassed pelvic areas, and in one case, treatment was directed to the whole body.

In the studies reporting the variables that reflect the performance of the LVAD, such as power, flow, and rotational speed, all report insignificant changes between pre- and post-irradiation values (2,11,13). None of the studies reported any disturbance in device performance.

Previously published case reports are summarized in Table 3 (2, 5-15). Most of the studies used 6 to 15 MV photon beams with prescribed doses within the range of 20–66 Gy delivered in 3–33 fractions. Mean doses received by LVAD ranged between 8–1922 cGy, and maximum doses to LVAD and its subparts varied according to laterality of the tumor up to 6830 cGy (10). There was no reported device malfunctioning, with the longest reported follow-up being 29 months. We believe that

this report will contribute to the current literature in several aspects, notably by reporting the successful delivery of radiotherapy in the first case with breast cancer primary and the second case with an implanted HeartWare LVAD. Furthermore, this report also reports the longest follow-up with 41 months and no device malformation.

With both *in vitro* and *in vivo* results stating the safe irradiation of LVAD and the review by Spano et al. (2) summarizing the recommendations, including ensuring a multidisciplinary approach, using beam energies <10 MV to minimize neutron contamination, ensuring a rapid response team is available, close monitoring of the patient, securing the extracorporeal parts, and interrogating the LVAD after each radiation session. In the presented case, contralaterality of the LVAD and primary tumor location made reducing radiation dose received by LVAD relatively simple, but in cases with close proximity between tumor site and the device, the radiotherapy becomes significantly more complex. Direct irradiation of the device may be unavoidable. In such situations, careful multidisciplinary planning is essential to balance optimal oncologic outcomes with device safety. Whenever feasible, attempts to reduce the dose received by the LVAD should be made, including advanced radiotherapy techniques such as intensity modulated radiotherapy or proton irradiation, or distancing the device from the radiotherapy field with techniques like deep inspiration breath hold.

Cancer patients with LVAD *in situ* pose a multifaceted challenge in radiotherapy in terms of treatment decision and technical considerations. The presented case described a patient who received adjuvant radiotherapy to the thoracic region, and yielded no evidence of device malfunction, thereby affirming its safe implementation in this case. There is limited published data regarding the safety of radiotherapy in patients with LVAD. More studies are needed in this area to ensure optimal patient safety and treatment decision-making.

Table 3. List of the studies reporting patients irradiated with VAD for various sites and techniques

Study	Year	Device	Diagnosis	Beam	Prescription dose (cGy)	Fraction	Max dose (cGy) to the device	Mean dose (cGy) to the device
Lasher et al. (5)	2008	Thoratec	Rectal adenocarcinoma	15 MV photon	4500	25	425	-
Netuka et al. (6)	2013	HM II	Hodgkin lymphoma	NR	NR	12	NR	NR
Scobioala et al. (7)	2015	Novacor LVAD Atlas II VR SN (St. Jude Medical, Saint Paul, Minnesota, US)	Lung squamous cell carcinoma	Conventional: 6/15 MV photon beams	2520	14	538	231
				SBRT: 6 MV	3500	5		
Emerson et al. (8)	2016	HM II	Gastroesophageal junction adenocarcinoma	15 MV photon	5040	NR	4900	1922
	2016	HM II	Lung adenocarcinoma	SBRT: 6 MV photon	5400	3	61	9.6
	2016	HM II	Lung cancer/vertebral mets	6/15 MV photon	2000/3000	NR	2450	1423
Ostertag-Hill et al. (9)	2018	HeartWare	Lung nodule	SBRT: 6 MV photon	5000	5	698	45
Spano et al. (2)	2019	HM III	Lung adenocarcinoma	SBRT: 6 MV photon	5000	5	VAD: 29	VAD: 8
							Outflow graft: 991	Outflow graft: 147
							Drive line: 34	Drive line: 11
Sato et al. (10)	2020	NR	Thymic carcinoma	6 MV photon	6600	33	Outflow graft: 6830	-
							VAD: 0	-
							CRT-D: 99	-
Schumer et al. (11)	2022	HM II	Lung squamous cell carcinoma	Proton beams	6000	30	NR	NR
Yousafzai et al. (12)	2022	HM III	Sternal osteosarcoma	NR	6660	NR	46.4	
Butt and Sheikh (13)	2023	HM III	Lung adenocarcinoma	SBRT	3000	5	NR	NR
	2023	HMIII	Lung small cell carcinoma	SBRT	5000	5	NR	NR
Webster et al. (14)	2024	HM III	Acute myeloblastic leukemia	16 MV photon	400	2	120	
			Lung adenocarcinoma	SBRT	42-52 Gy	4	<200	
Hayashi et al. (15)	2024		Lung adenocarcinoma	SBRT	42-52 Gy	4	<200	
			Lung adenocarcinoma	SBRT	42-52 Gy	4	<200	
Alanyalı et al.	2025	HeartWare	Breast invasive ductal carcinoma	6 MV photon	5000	25	Outflow graft: 767	Outflow graft: 227
							VAD: 24	VAD: 9

NR: Not reported; LVAD: Left ventricular assist devices

Ethics

Informed Consent: Written informed consent was taken from the patient.

Footnotes

Authorship Contributions

Surgical and Medical Practices: S.A., E.K., M.K., Ü.K., S.N.; Concept: S.A., E.K., Ü.K., S.N.; Design: S.A., E.K., M.K., Ü.K., S.N.; Data Collection or Processing: S.A., E.K., S.N.; Analysis or Interpretation: S.A., E.K., S.N.; Literature Search: S.A., E.K.; Writing: S.A., E.K.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

- Molina EJ, Shah P, Kiernan MS, Cornwell WK 3rd, Copeland H, Takeda K, et al. The Society of Thoracic Surgeons Intermacs 2020 annual report. *Ann Thorac Surg.* 2021; 111: 778-792. (PMID: 33465365) [\[Crossref\]](#)
- Spano G, Stutz E, Elicin O, Hugi B, Henzen D, Fürholz M, et al. Is it safe to irradiate the newest generation of ventricular assist devices? A case report and systematic literature review. *Artif Organs.* 2020; 44: 449-456. (PMID: 31769042) [\[Crossref\]](#)
- Sindhu KK, Shi C, Moss N, Lin H, Zhang J, Hu L, et al. The effects of pencil beam scanning proton beam therapy on a heartmate 3 left ventricular assist device: implications for patient safety. *ASAIO J.* 2022; 68: e145-e147. (PMID: 35537112) [\[Crossref\]](#)
- Benali K, Lloyd MS, Petrosyan A, Rigal L, Quivrin M, Bessieres I, et al. Cardiac stereotactic radiation therapy for refractory ventricular arrhythmias in patients with left ventricular assist devices. *J Cardiovasc Electrophysiol.* 2024; 35: 206-213. (PMID: 38018417) [\[Crossref\]](#)
- Lasher DE, Wojcicka JB, Malcom R, Shears LL. Case study of radiation therapy treatment of a patient with a cardiac ventricular assist device. *J Appl Clin Med Phys.* 2008; 9: 214-220. (PMID: 19020490) [\[Crossref\]](#)
- Netuka I, Stepankova P, Urban M, Maly J, Szarszoi O, Dorazilova Z, et al. Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of Hodgkin's lymphoma? Not any more. *ASAIO J.* 2013; 59: 320-321. (PMID: 23644622) [\[Crossref\]](#)
- Scobioala S, Ernst I, Moustakis C, Haverkamp U, Martens S, Eich HT. A case of radiotherapy for an advanced bronchial carcinoma patient with implanted cardiac rhythm machines as well as heart assist device. *Radiat Oncol.* 2015; 10: 78. (PMID: 25885061) [\[Crossref\]](#)
- Emerson LY, Deek MP, Almendral J, Jabbour SK. Radiation therapy in patients with left ventricular assist device: a case report and literature review. *Pract Radiat Oncol.* 2016; 6: e145-e147. (PMID: 27017262) [\[Crossref\]](#)
- Ostertag-Hill CA, Mudd J, Werle DP, Tieu BH, Nabavizadeh N. Safe delivery of lung stereotactic body radiation therapy in a patient with a left ventricular assist device and implantable cardioverter defibrillator. *Clin Case Rep.* 2018; 6: 1704-1707. (PMID: 30214746) [\[Crossref\]](#)
- Sato GE, Matsuo Y, Kanemitsu H, Minatoya K, Nakajima D, Date H, et al. Safe delivery of postoperative radiotherapy for thymic carcinoma located on the outflow graft of a left ventricular assist device. *JTO Clin Res Rep.* 2020; 2: 100101. (PMID: 34589971) [\[Crossref\]](#)
- Schumer EM, Schettle S, Stulak JM, Rosenbaum AN. First report of proton beam therapy in a patient with a left ventricular assist device. *ASAIO J.* 2022; 68: e84-e86. (PMID: 35503645) [\[Crossref\]](#)
- Yousafzai OK, Stewart SM, Zaman MO, Ingenito A, Kim B. Sternal radiation for osteosarcoma treatment in a patient with left ventricular assist device. *JACC.* 2022; 79 (9_Supplement): 2579. [\[Crossref\]](#)
- Butt N, Sheikh FH. Feasibility of mediastinal radiation use in heartmate 3 LVAD recipients with cancer. *Methodist Debaque Cardiovasc J.* 2023; 19: 15-19. (PMID: 36742441) [\[Crossref\]](#)
- Webster M, Dona Lemus OM, Zheng D, Wancura JN, Tanny S, Sakthivel G, et al. Case study with dosimetric analysis: total body irradiation to a patient with a left ventricular assist device. *Clin Case Rep.* 2024; 12: e8868. (PMID: 38756618) [\[Crossref\]](#)
- Hayashi K, Ishikawa H, Fujiwara K, Nakai M, Ono H, Fumimoto Y, et al. Stereotactic ablative radiotherapy for early-stage lung cancer in patients with left ventricular assist device: a case series. *Anticancer Res.* 2024; 44: 4113-4117. (PMID: 39197891) [\[Crossref\]](#)